Loading organizations...
§ Private Profile · Hsinchu, T'ai-wan, Taiwan
Biosimilar developer and CDMO for global biopharmaceutical clients, creating high-quality, affordable biologics medicines from Taiwan.
Eden Biologics is a biopharmaceutical company based in Hsinchu, Taiwan, that develops proprietary biosimilars and provides contract development and manufacturing organization services for global clients. The organization utilizes proprietary engineering technologies to support cell line development and regulatory filings, having completed investigational new drug and clinical trial application submissions across more than 20 countries and regions. The firm operates with financial backing from major investors including Kleiner Perkins and Biomark Capital, while its leadership team brings experience from organizations like Shanghai Henlius Biotech. In recent years, the company resolved civil claims with Genentech and entered a non-prosecution agreement with the United States Department of Justice following a trade secret investigation into former employees. Eden Biologics was originally founded in 2012, though specific founder names are not publicly disclosed, and is currently led by CEO Steve Lee.
Eden Biologics has raised $80.6M across 2 funding rounds.
Eden Biologics has raised $80.6M in total across 2 funding rounds.
Eden Biologics has raised $80.6M across 2 funding rounds. Most recently, it raised $45.6M Series C in May 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 12, 2015 | $45.6M Series C | — | Liwick Investment Management, Milestone Capital, Sungent BioVenture | Announced |
| Jun 20, 2014 | $35M Series B | Milestone Capital | Allen Chao, Biomark Capital, CDIB Capital Group, Fubon Ventures, Hotung Venture Group, Kleiner Perkins, President International Development Corporation, Taian Venture Capital, Taishin Financial Holdings | Announced |
Eden Biologics has raised $80.6M in total across 2 funding rounds.
Eden Biologics's investors include Liwick Investment Management, Milestone Capital, Sungent BioVenture, Allen Chao, Biomark Capital, CDIB Capital Group, Fubon Ventures, Hotung Venture Group, Kleiner Perkins, President International Development Corporation, Taian Venture Capital, Taishin Financial Holdings.